Pages that link to "Q70214647"
Jump to navigation
Jump to search
The following pages link to Dosing implications of altered gentamicin disposition in patients with cystic fibrosis (Q70214647):
Displaying 50 items.
- Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis (Q28361867) (← links)
- Cefsulodin sodium therapy in cystic fibrosis patients (Q30451333) (← links)
- Pharmacokinetic and pharmacodynamic data collection in children and neonates. A quiet frontier (Q31006578) (← links)
- Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis (Q34347531) (← links)
- Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis (Q35191579) (← links)
- Increased aminoglycoside dosage requirements in hematologic malignancy (Q35253342) (← links)
- Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis (Q35563227) (← links)
- Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients (Q35648082) (← links)
- Single-dose pharmacokinetics of cefsulodin in patients with cystic fibrosis (Q35759777) (← links)
- Azlocillin pharmacokinetics in patients with cystic fibrosis (Q35760049) (← links)
- Levofloxacin pharmacokinetics in adult cystic fibrosis (Q36137356) (← links)
- Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations (Q36264445) (← links)
- Pharmacokinetics of drugs in cystic fibrosis (Q37289749) (← links)
- Antimicrobial therapy in neonates, infants and children. (Q38756066) (← links)
- Clinical pharmacokinetics in infants and children. A reappraisal (Q38756081) (← links)
- Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis (Q39097052) (← links)
- Clinical pharmacology of antibiotics and other drugs in cystic fibrosis (Q39654236) (← links)
- Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance (Q39673276) (← links)
- High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients (Q39686183) (← links)
- Cephalosporin therapeutics in cystic fibrosis (Q39732196) (← links)
- Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis (Q39849680) (← links)
- Clinical Pharmacology of Aminoglycoside Antibiotics in Pediatrics (Q40145558) (← links)
- Advances in the diagnosis and management of cystic fibrosis (Q40191888) (← links)
- Cystic fibrosis--a challenging masquerader. (Q40211134) (← links)
- Normal volume of distribution of tobramycin in a mother and daughter with a CFTR splice mutation (1717 - 1G --> A). (Q40649925) (← links)
- Pharmacokinetics of anti-infective agents in paediatric patients (Q40686147) (← links)
- Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. (Q40829169) (← links)
- Renal clearance of gentamicin in cystic fibrosis (Q41589144) (← links)
- Kinetic parameters of amikacin in cystic fibrosis children (Q43920407) (← links)
- Enhanced hepatic drug clearance in patients with cystic fibrosis (Q44424763) (← links)
- Gentamicin pharmacokinetics in cystic fibrosis (Q44794850) (← links)
- Aminoglycoside induced ototoxicity in patients with cystic fibrosis (Q44858433) (← links)
- Tobramycin dosage recommendation in patients with cystic fibrosis (Q45034152) (← links)
- Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis (Q46172261) (← links)
- Pharmacokinetics of amikacin in cystic fibrosis: a study of bronchial diffusion (Q50581097) (← links)
- Assessment of glomerular filtration rate and effective renal plasma flow in cystic fibrosis. (Q52667064) (← links)
- Hypothetical framework for enhanced renal tubular secretion of drugs in cystic fibrosis. (Q53767678) (← links)
- Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis (Q57151052) (← links)
- Introduction to pharmacokinetics: aminoglycosides in cystic fibrosis as a prototype (Q68873401) (← links)
- Individualizing gentamicin dosage in patients with cystic fibrosis: limitations to pharmacokinetic approach (Q69728555) (← links)
- Altered PABA pharmacokinetics in cystic fibrosis. Implications for bentiromide test (Q69871945) (← links)
- Ciprofloxacin pharmacokinetics in patients with cystic fibrosis (Q69991033) (← links)
- Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis (Q70113968) (← links)
- Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis (Q70270553) (← links)
- Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study (Q70363398) (← links)
- Applied pharmacokinetics in acute exacerbations of Pseudomonas aeruginosa pneumonia in cystic fibrosis (Q70485414) (← links)
- Tobramycin serum level monitoring in young patients with normal renal function (Q70670604) (← links)
- Cloxacillin absorption and disposition in cystic fibrosis (Q70678191) (← links)
- Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis (Q71001102) (← links)
- Gentamicin disposition in patients with cystic fibrosis: erratum (Q71329619) (← links)